<DOC>
	<DOCNO>NCT02614833</DOCNO>
	<brief_summary>The propose Phase IIb clinical study aim investigate safety efficacy active immunotherapy IMP321 combination ( adjunctive ) paclitaxel chemotherapy patient hormone receptor-positive metastatic breast cancer .</brief_summary>
	<brief_title>IMP321 Adjunctive Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma</brief_title>
	<detailed_description>This multicentre , placebo-controlled , double-blind , 1:1 randomise Phase IIb study female hormone receptor-positive metastatic breast cancer patient . The study comprise two stage . Stage 1 open-label , safety run-in stage consist cohort 1 2 confirm ( RPTD ) IMP321 combination paclitaxel . Stage 2 placebo-controlled , double-blind randomisation stage , paclitaxel + IMP321 RPTD compare paclitaxel + placebo .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Able give write informed consent comply protocol 2 . Stage IV oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma , histologically proven biopsy primary tumour and/or metastasis 3 . Female age 18 year 4 . Patients indicate receive first line chemotherapy weekly paclitaxel 5 . Evidence measurable disease define Response Evaluation Criteria version 1.1 6 Laboratory criterion : haematology biochemistry result within limit normally expect patient population . 1 . Prior chemotherapy metastatic breast adenocarcinoma 2 . Diseasefree interval less twelve month last dose adjuvant chemotherapy 3 . Inflammatory carcinoma 4 . Candidate treatment trastuzumab ( Her2/neu target agent ) 5 . Systemic chemotherapy , radiation therapy investigational agent within 4 week , endokrine therapy within 1 week prior first dose study treatment completion study treatment 6 . Symptomatic known cerebral and/or leptomeningeal metastases 7 . Serious intercurrent infection 8 . Evidence severe uncontrolled cardiac disease ( NYHA IIIIV ) within 6 month prior first dose study treatment 9 . Active acute chronic infection 10 . Active autoimmune disease require immunosuppressive therapy 11 . Previous malignancy within last three year breast carcinoma 12 . Patients prior organ stem cell transplantation 13 . Any condition require continuous systemic treatment either corticosteroid immunosuppressive medication within 4 week prior first dose study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hormone receptor positive</keyword>
</DOC>